Cutaneous Phosphorlyated α-synuclein Detection as a Biomarker of Synucleinopathy
Status: Completed
Location: See all (23) locations...
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY
The Synuclein-One Study will be evaluating α-synuclein in patients with Parkinson's disease, Multiple System Atrophy, Dementia with Lewy bodies and Pure Autonomic Failure. Using a simple diagnostic test will improve clinical accuracy in diagnosing, earlier diagnosis, and distinguish between neurodegenerative diseases.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 40
Maximum Age: 99
View:
• Male and female between 40-99 years of age
• Prior clinical diagnosis of Parkinson's disease, Multiple System Atrophy, Dementia with Lewy bodies or Pure Autonomic Failure
• Health Subjects, no history of clinical or symptoms suggestive with synucleinopathy
Locations
United States
Arizona
MD First Research
Chandler
CND Life Sciences
Phoenix
Movement Disorders Center of Arizona
Scottsdale
California
The Neuro Center
Carlsbad
Providence St. John's Health
Santa Monica
Colorado
Rocky Mountain Movement Disorders Center, PC
Englewood
Florida
Aventura Neurology
Aventura
Parkinson's Disease and Movement Disorders Center of Boca Raton
Boca Raton
UF College of Medicine
Gainesville
Parkinson's Disease Treatment Center SWFL
Port Charlotte
Illinois
NorthShore University Health System
Evanston
Massachusetts
Beth Israel Lahey Health
Boston
Boston Medical Center
Boston
Minnesota
Mayo Clinic
Rochester
North Carolina
Duke University Medical Center
Durham
New York
NYU Medical Center
New York
SouthShore Neurologic
Patchogue
Oregon
Providence Brain & Spine Institute
Portland
Tennessee
Vanderbilt University Medical Center
Nashville
Texas
UTSouthwestern
Dallas
Texas Movement Disorders Specialists
Georgetown
Washington
Evergreen Health
Kirkland
Swedish Neuroscience Research
Seattle
Time Frame
Start Date: 2021-01-04
Completion Date: 2023-11-08
Participants
Target number of participants: 428
Treatments
Parkinson's disease
Looking for 105 patients with a clinically established diagnosis of Parkinson's disease between 40-99 years of age.
Multiple System Atrophy
Looking for 40 patients with a clinically established diagnosis of Multiple System Atrophy between 40-99 years of age.
Dementia with Lewy bodies
Looking for 95 patients with a clinically established diagnosis of Dementia with Lewy bodies between 40-99 years of age.
Pure Autonomic Failure
Looking for 60 patients with a clinically established diagnosis of Pure Autonomic Failure between 40-99 years of age.
Healthy Controls
No history of clinical or symptoms suggestive of Parkinson's disease, Multiple System Atrophy, Dementia with Lewy bodies or Pure Autonomic Failure between 40-99 years of age.
Authors
Alex Barboi, Daniel Claassen, Marie Saint-Hilaire, Oleg Yerstein, Pravin Khemani, Melita Petrossian, Steven Vernino, Mark Gudesblatt, Julie Schwartzbard, Nikolaus McFarland, Gregory Sahagian, Hemant Pandey, Ramon Gil, Pinky Agarwal, Wolfgang Singer, Michael Soileau, Rajeev Kumar, Horacio Kaufmann, Stuart Isaacson
Related Therapeutic Areas
Sponsors
Leads: CND Life Sciences